Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

The REMS Report Card: FDA Using New Tools For One-Third Of New Drugs In First Six Months

Executive Summary

FDA has used its new authority to impose a Risk Evaluation and Mitigation Strategy on one-third of all new molecular entities approved since the REMS provisions of the FDA Amendments Act took effect at the end of March

You may also be interested in...



Industry Wants More Transparency From Agency On REMS Determinations

SAN DIEGO - Industry is hoping an upcoming Risk Evaluation and Mitigation Strategy guidance document will outline a more transparent process regarding the FDA's REMS decisions

Industry Wants More Transparency From Agency On REMS Determinations

SAN DIEGO - Industry is hoping an upcoming Risk Evaluation and Mitigation Strategy guidance document will outline a more transparent process regarding the FDA's REMS decisions

Post-Marketing Trial Key To Saxagliptin Approval – And Commercial Potential

Bristol-Myers Squibb and AstraZeneca will need to design a precedent-setting cardiovascular outcomes study for saxagliptin before the drug will be approved by the agency

Related Content

UsernamePublicRestriction

Register

RS150923

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel